Long-Term Data for Givinostat Strengthens Safety Profile in Duchenne Muscular Dystrophy

(MedPage Today) — SAN FRANCISCO — Givinostat (Duvyzat) had a manageable long-term safety profile in Duchenne muscular dystrophy, data from an open-label extension study suggest. Most treatment-emergent adverse events (TEAEs) were mild to…